Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 2.70 ($0.03) and last traded at GBX 2.70 ($0.03), with a volume of 1791365 shares trading hands. The stock had previously closed at GBX 2.90 ($0.04).
Wall Street Analysts Forecast Growth
Separately, Shore Capital reiterated a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, January 2nd.
Check Out Our Latest Report on POLB
Poolbeg Pharma Stock Up 0.4 %
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Further Reading
- Five stocks we like better than Poolbeg Pharma
- Stock Sentiment Analysis: How it Works
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- When to Sell a Stock for Profit or Loss
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
